Patents by Inventor Matthew A. Movsesian

Matthew A. Movsesian has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS FOR MODULATING CYCLIC NUCLEOTIDE-MEDIATED SIGNALING IN CARDIAC MYOCYTES AND COMPOSITIONS
    Publication number: 20190017035
    Abstract: The invention provides a polypeptide possessing anti-hypertrophic activity in a cardiac myocyte, wherein the polypeptide is a mutant variant derived from wild-type PDE3A1 protein and wherein the wild-type PDE3A1 protein has the amino acid sequence given in SEQ ID NO:1 at amino acid position 146 to 1141.
    Type: Application
    Filed: May 9, 2018
    Publication date: January 17, 2019
    Inventors: Matthew Movsesian, Manuela Zaccolo
  • Methods for modulating cyclic nucleotide-mediated signaling in cardiac myocytes and compositions
    Patent number: 9994830
    Abstract: The invention provides a polypeptide possessing anti-hypertrophic activity in a cardiac myocyte, wherein the polypeptide is a mutant variant derived from wild-type PDE3A1 protein and wherein the wild-type PDE3A1 protein has the amino acid sequence given in SEQ ID NO:1 at amino acid position 146 to 1141.
    Type: Grant
    Filed: July 15, 2015
    Date of Patent: June 12, 2018
    Assignee: The United States of America as Represented by the Department of Veterans Affairs
    Inventors: Matthew Movsesian, Manuela Zaccolo
  • Isoform-selective inhibitors and activators of PDE3 cyclic nucleotide phosphodiesterases
    Patent number: 9513288
    Abstract: The present invention concerns methods and compositions related to type 3 phosphodiesterases (PDE3). Certain embodiments concern isolated peptides corresponding to various PDE3A isoforms and/or site-specific mutants of PDE3A isoforms, along with expression vectors encoding such isoforms or mutants. In specific embodiments, methods for identifying isoform-selective inhibitors or activators of PDE3 are provided, along with methods of use of such inhibitors or activators in the treatment of dilated cardiomyopathy, pulmonary hypertension and/or other medical conditions related to PDE3 effects on cAMP levels in different intracellular compartments.
    Type: Grant
    Filed: November 14, 2013
    Date of Patent: December 6, 2016
    Assignees: The United States of America as Represented by the Department of Veterans Affairs, University of Utah Research Foundation
    Inventor: Matthew A. Movsesian
  • Isoform-selective inhibitors and activators of PDE3 cyclic nucleotide phosphodiesterases
    Patent number: 9513289
    Abstract: The present invention concerns methods and compositions related to type 3 phosphodiesterases (PDE3). Certain embodiments concern isolated peptides corresponding to various PDE3A isoforms and/or site-specific mutants of PDE3A isoforms, along with expression vectors encoding such isoforms or mutants. In specific embodiments, methods for identifying isoform-selective inhibitors or activators of PDE3 are provided, along with methods of use of such inhibitors or activators in the treatment of dilated cardiomyopathy, pulmonary hypertension and/or other medical conditions related to PDE3 effects on cAMP levels in different intracellular compartments.
    Type: Grant
    Filed: March 27, 2014
    Date of Patent: December 6, 2016
    Assignees: The United Sates of America, as Represented by the Department of Veterans Affairs, University of Utah Research Foundation
    Inventor: Matthew A. Movsesian
  • METHODS FOR MODULATING CYCLIC NUCLEOTIDE-MEDIATED SIGNALING IN CARDIAC MYOCYTES AND COMPOSITIONS
    Publication number: 20160083701
    Abstract: The invention provides a polypeptide possessing anti-hypertrophic activity in a cardiac myocyte, wherein the polypeptide is a mutant variant derived from wild-type PDE3A1 protein and wherein the wild-type PDE3A1 protein has the amino acid sequence given in SEQ ID NO:1 at amino acid position 146 to 1141.
    Type: Application
    Filed: July 15, 2015
    Publication date: March 24, 2016
    Inventors: Matthew Movsesian, Manuela Zaccolo
  • ISOFORM-SELECTIVE INHIBITORS AND ACTIVATORS OF PDE3 CYCLIC NUCLEOTIDE PHOSPHODIESTERASES
    Publication number: 20150119332
    Abstract: The present invention concerns methods and compositions related to type 3 phosphodiesterases (PDE3). Certain embodiments concern isolated peptides corresponding to various PDE3A isoforms and/or site-specific mutants of PDE3A isoforms, along with expression vectors encoding such isoforms or mutants. In specific embodiments, methods for identifying isoform-selective inhibitors or activators of PDE3 are provided, along with methods of use of such inhibitors or activators in the treatment of dilated cardiomyopathy, pulmonary hypertension and/or other medical conditions related to PDE3 effects on cAMP levels in different intracellular compartments.
    Type: Application
    Filed: November 14, 2013
    Publication date: April 30, 2015
    Applicants: UNIVERSITY OF UTAH RESEARCH FOUNDATION, THE UNITED STATES GOVERNMENT, AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS
    Inventor: Matthew A. Movsesian
  • ISOFORM-SELECTIVE INHIBITORS AND ACTIVATORS OF PDE3 CYCLIC NUCLEOTIDE PHOSPHODIESTERASES
    Publication number: 20140350047
    Abstract: The present invention concerns methods and compositions related to type 3 phosphodiesterases (PDE3). Certain embodiments concern isolated peptides corresponding to various PDE3A isoforms and/or site-specific mutants of PDE3A isoforms, along with expression vectors encoding such isoforms or mutants. In specific embodiments, methods for identifying isoform-selective inhibitors or activators of PDE3 are provided, along with methods of use of such inhibitors or activators in the treatment of dilated cardiomyopathy, pulmonary hypertension and/or other medical conditions related to PDE3 effects on cAMP levels in different intracellular compartments.
    Type: Application
    Filed: March 27, 2014
    Publication date: November 27, 2014
    Applicants: University of Utah Research Foundation, The United States Government, as represented by the Department of Veterans Affairs
    Inventor: Matthew A. Movsesian
  • Isoform-selective inhibitors and activators of PDE3 cyclic nucleotide phosphodiesterases
    Patent number: 8722866
    Abstract: The present invention concerns methods and compositions related to type 3 phosphodiesterases (PDE3). Certain embodiments concern isolated peptides corresponding to various PDE3A isoforms and/or site-specific mutants of PDE3A isoforms, along with expression vectors encoding such isoforms or mutants. In specific embodiments, methods for identifying isoform-selective inhibitors or activators of PDE3 are provided, along with methods of use of such inhibitors or activators in the treatment of dilated cardiomyopathy, pulmonary hypertension and/or other medical conditions related to PDE3 effects on cAMP levels in different intracellular compartments.
    Type: Grant
    Filed: January 18, 2007
    Date of Patent: May 13, 2014
    Assignee: The United States of America, as Represented by the Department of Veterans Affairs
    Inventor: Matthew A. Movsesian
  • PDE1 AS A TARGET THERAPEUTIC IN HEART DISEASE
    Publication number: 20120070443
    Abstract: Disclosed are compositions and methods related to inhibition of PDE1.
    Type: Application
    Filed: December 2, 2009
    Publication date: March 22, 2012
    Applicant: UNIVERSITY OF UTAH RESEARCH FOUNDATION
    Inventor: Matthew Movsesian
  • ISOFORM-SELECTIVE INHIBITOR AND ACTIVATORS OF PDE3 CYCLIC NUCLEOTIDE PHOSPHODIESTERASES
    Publication number: 20100267046
    Abstract: The present invention concerns methods and compositions related to type 3 phosphodiesterases (PDE3). Certain embodiments concern isolated peptides corresponding to various PDE3A isoforms and/or site-specific mutants of PDE3A isoforms, along with expression vectors encoding such isoforms or mutants. In specific embodiments, methods for identifying isoform-selective inhibitors or activators of PDE3 are provided, along with methods of use of such inhibitors or activators in the treatment of dilated cardiomyopathy, pulmonary hypertension and/or other medical conditions related to PDE3 effects on cAMP levels in different intracellular compartments.
    Type: Application
    Filed: January 18, 2007
    Publication date: October 21, 2010
    Applicant: University of Utah Research Foundation
    Inventor: Matthew A. Movsesian
  • Isoform-selective inhibitors and activators of PDE3 cyclic nucleotide phosphodiesterases
    Publication number: 20030158133
    Abstract: The present invention concerns methods and compositions related to type 3 phosphodiesterases (PDE3). Certain embodiments concern isolated peptides corresponding to various PDE3A isoforms and/or site-specific mutants of PDE3A isoforms, along with expression vectors encoding such isoforms or mutants. In specific embodiments, methods for identifying isoform selective inhibitors or activators of PDE3 are provided, along with methods of use of such inhibitors or activators in the treatment of dilated cardiomyopathy, pulmonary hypertension and/or other medical conditions related to PDE3 effects on cAMP levels in different intracellular compartments.
    Type: Application
    Filed: June 19, 2002
    Publication date: August 21, 2003
    Inventor: Matthew A. Movsesian